Prandin is a brand-name medication that contains repaglinide as its active ingredient. It belongs to the class of rapid-acting insulin secretagogues used in the management of type 2 diabetes mellitus. Prandin is supplied as an oral pill in three strengths: 0.5 mg, 1 mg, and 2 mg. In Hong Kong, it is available only with a prescription and is regulated by the Department of Health’s Drug Office.
Repaglinide stimulates the pancreas to release insulin in response to meals. It binds to the sulfonylurea receptor 1 (SUR1) subunit of the ATP-sensitive potassium (KATP) channel on pancreatic β-cells. This action closes the KATP channel, depolarizes the cell membrane, and triggers calcium influx, prompting insulin granule exocytosis.
Because its effect closely aligns with post-meal glucose spikes, repaglinide can be taken with each main meal to improve postprandial blood-sugar control.
Prandin is approved in Hong Kong for the treatment of type 2 diabetes mellitus when diet, exercise, and other oral antidiabetic agents (e.g., metformin) do not achieve adequate glycaemic control. It is indicated for adult patients who require a rapid-acting oral agent to lower post-prandial glucose levels.
Patients should provide a complete medication list-including over-the-counter drugs, supplements, and herbal products-to their healthcare provider before starting Prandin.
Standard dosing:
Initiate treatment with 0.5 mg taken before the first main meal of the day.
The dose may be increased to 1 mg before each main meal based on glycaemic response, not exceeding 2 mg per meal or 6 mg per day.
Administration tips:
Swallow the pill whole with a glass of water.
Do not crush or chew unless advised by a pharmacist.
If a dose is missed, take it as soon as the next meal occurs; do not double the dose.
Renal or hepatic impairment: Start with a lower dose (e.g., 0.5 mg) and titrate cautiously.
Overdose: Symptoms may include profound hypoglycaemia, seizures, or loss of consciousness. Seek emergency medical care; treatment focuses on rapid glucose administration. No specific antidote exists.
Discontinuation: When stopping repaglinide, tapering is generally unnecessary, but patients should monitor blood glucose closely and discuss transition plans with a clinician to avoid rebound hyperglycaemia.
This article provides educational information about Prandin and is not a substitute for professional medical advice. Treatment decisions, including the use of any medication for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Prandin is not contraindicated in patients with a stable gastric ulcer, but it should be taken with food to minimize gastrointestinal irritation. If you experience worsening abdominal pain, contact your healthcare provider.
Both classes stimulate insulin release, but repaglinide has a shorter half-life and quicker onset, allowing dosing with each main meal. This reduces the risk of prolonged hypoglycaemia compared with longer-acting sulfonylureas.
Repaglinide is not a controlled substance and is not screened for in standard workplace or anti-doping drug tests. However, always disclose all medications to testing authorities if required.
Consume 15 g of fast-acting carbohydrate (e.g., glucose tablets, fruit juice). Re-check blood glucose after 15 minutes and repeat if still low. If symptoms persist, seek medical assistance.
Yes, provided you carry the medication in its original labelled container, along with a copy of the prescription. Some countries may require a doctor’s note; verify requirements before travel.
Intense physical activity can increase insulin sensitivity and raise hypoglycaemia risk. Consider taking a lower dose before the exercise session or monitor glucose closely during and after activity.
Prandin can be added to basal insulin regimens to improve post-prandial control, but dose adjustments and close monitoring are essential to avoid hypoglycaemia. Discuss the combination with your diabetes team.
Common excipients include lactose, microcrystalline cellulose, and magnesium stearate. If you have known allergies or sensitivities, review the full product insert or ask a pharmacist.
The tablet’s stability is maintained as long as it remains sealed in its original container, protected from moisture and heat. Once the bottle is opened, use the medication within the expiration date printed on the label.
Prandin is listed in the Hong Kong Hospital Authority’s formulary for type 2 diabetes. It may be subsidised for eligible patients; consult your clinic for enrollment details and cost information.
